Shenzhen Chipscreen Biosciences announced that its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd., recently received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration. The application is to modify the drug information and drug interaction information for patients with impaired liver and kidney function in the instruction manual for SGLT2 sodium-glucose cotransporter-2 inhibitor tablets. The approval conclusion is to approve the supplementary application for modifying the drug information and drug interaction information for patients with impaired liver and kidney function in the instruction manual for SGLT2 sodium-glucose cotransporter-2 inhibitor tablets. SGLT2 sodium-glucose cotransporter-2 inhibitor is a new mechanism insulin sensitizer independently developed by the company, belonging to the category 1 new drug in China and a special achievement of the national 'Major New Drug Creation' project. It has been approved for monotherapy of type 2 diabetes and combination therapy with metformin for type 2 diabetes, and was first included in the national medical insurance catalog in 2023. It has recently successfully renewed its original price until December 31, 2026. The revision of the instruction manual this time is expected to have a positive guiding effect on the clinical use promotion of SGLT2 sodium-glucose cotransporter-2 inhibitor tablets, but it will not have a significant impact on the company's operation performance in the short term.